Pliant's Novel Integrin Inhibitor Targets Immunotherapy-Resistant Cancers

SOUTH SAN FRANCISCO, CA – May 21, 2026 – In the relentless battle against advanced cancer, immunotherapy has been a revolutionary force, but its power is not universal. A significant number of patients find their tumors are either initially unresponsive or eventually develop resistance to these life-extending treatments, leaving them with limited and often more toxic options. Pliant Therapeutics, a clinical-stage biopharmaceutical company, is now poised to address this critical challenge with a novel drug, PLN-101095, and will present new data at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The company announced it will feature a poster presentation on its FORTIFY trial, a Phase 1b study evaluating PLN-101095 in combination with the widely used immune checkpoint inhibitor (ICI) pembrolizumab. The trial focuses on patients with advanced solid tumors that have become refractory to prior ICI therapy, a population with a dire unmet medical need. The presentation, led by Dr. Timothy A. Yap of the M.D. Anderson Cancer Center, is expected to draw significant attention from oncologists and researchers eager for new strategies to overcome one of modern oncology's most formidable hurdles.

A Novel Attack on Cancer's Defenses

Unlike conventional checkpoint inhibitors that directly target proteins like PD-1 or PD-L1, Pliant's PLN-101095 employs a fundamentally different strategy. It is a first-in-class, orally administered small molecule designed as a dual inhibitor of integrins αvβ8 and αvβ1. These integrins are key culprits in activating a protein called transforming growth factor-beta (TGF-β).

In a healthy body, TGF-β plays a role in regulating cellular processes, but many cancers hijack this pathway for their own survival. Activated TGF-β creates a powerfully immunosuppressive tumor microenvironment (TME), effectively building a fortress around the tumor that shields it from the body's immune system. This immunosuppressive shield is a primary reason why checkpoint inhibitors like pembrolizumab can fail. They are designed to release the 'brakes' on T-cells, but if those T-cells can't physically infiltrate the tumor, the therapy is rendered ineffective.

PLN-101095 aims to dismantle this fortress. By blocking the αvβ8 and αvβ1 integrins, the drug prevents the activation of TGF-β within the TME. The scientific rationale is that this will reduce immunosuppression, allow cancer-fighting immune cells to flood the tumor, and thereby re-sensitize the cancer to the effects of a checkpoint inhibitor. Preclinical studies have supported this hypothesis, demonstrating that the drug, particularly in combination with an anti-PD-1 antibody, could shrink tumors and increase the presence of critical CD8+ T cells in the tumor microenvironment.

Hope for the Unresponsive

The challenge of ICI resistance is immense. While more than 40% of U.S. cancer patients are estimated to be eligible for checkpoint inhibitors, fewer than 13% ultimately respond. For those with advanced non-small cell lung cancer (NSCLC), clear cell renal cell carcinoma (RCC), or other solid tumors, seeing an initial response to immunotherapy only to have the disease progress again is a devastating setback. The FORTIFY trial is designed specifically for this group.

The Phase 1b open-label study is enrolling three distinct cohorts of patients whose advanced or metastatic cancers have progressed despite ICI treatment: those with NSCLC, those with clear cell RCC, and a broader group with tumors characterized by a high tumor mutational burden (TMB). The trial's design is notable. Patients first receive PLN-101095 as a monotherapy for 14 days before pembrolizumab is added to the regimen. This approach may help researchers understand the drug's standalone effects on the tumor microenvironment before assessing its synergistic potential in combination therapy.

For these patients, whose treatment pathways are narrowing, the prospect of a therapy that could make their tumors vulnerable to immunotherapy once more represents a significant source of hope. Success in the FORTIFY trial could validate a new therapeutic paradigm for a large and growing patient population.

Pliant's Strategic Play in a High-Stakes Market

For Pliant Therapeutics, PLN-101095 represents a strategic expansion from its work in fibrotic diseases into the highly competitive and lucrative oncology market. As a clinical-stage company, its future is heavily tied to the success of its lead programs. While the company's stock has faced headwinds, it maintains a strong balance sheet with a projected cash runway through 2028, giving it the financial stability to pursue aggressive development of its pipeline.

PLN-101095 is the cornerstone of its oncology ambitions. A positive outcome could not only provide a new treatment option for patients but also validate Pliant's entire integrin-focused discovery platform, potentially attracting partnerships and unlocking further value. The market for therapies that can overcome ICI resistance is vast and fiercely competitive, but Pliant's first-in-class mechanism gives it a unique position.

The upcoming ASCO presentation is a critical milestone. It offers the company a premier stage to showcase its scientific progress to the global oncology community, including potential partners, investors, and key opinion leaders. The data shared will be scrutinized for signals of safety and, most importantly, preliminary evidence of antitumor activity.

Early signs have been positive. Data from the Phase 1a dose-escalation portion of the study, presented at the American Association for Cancer Research (AACR) meeting in April 2026, were described as encouraging. Those results showed that PLN-101095 was well-tolerated and demonstrated anti-tumor activity in combination with pembrolizumab, with some patients showing deepening responses over time. An investigator involved in the early-stage study noted that the initial human data suggest this novel approach of selectively targeting αvβ8 and αvβ1 holds promise for treating patients with advanced solid tumors resistant to checkpoint inhibitors. The full data set to be unveiled at the Chicago conference will be critical in determining if this novel mechanism can truly reshape the treatment landscape for some of the most challenging cancers.